Thrivent Financial for Lutherans Has $23.94 Million Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Thrivent Financial for Lutherans grew its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 129,120 shares of the company's stock after acquiring an additional 18,540 shares during the quarter. Thrivent Financial for Lutherans owned about 0.43% of Inspire Medical Systems worth $23,937,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of INSP. Harbour Investments Inc. lifted its position in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after purchasing an additional 99 shares during the period. Monimus Capital Management LP bought a new stake in shares of Inspire Medical Systems during the 4th quarter worth approximately $5,099,000. Commonwealth Equity Services LLC boosted its position in shares of Inspire Medical Systems by 7.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 7,984 shares of the company's stock worth $1,480,000 after acquiring an additional 575 shares in the last quarter. Swiss National Bank increased its stake in Inspire Medical Systems by 1.0% in the fourth quarter. Swiss National Bank now owns 58,600 shares of the company's stock valued at $10,863,000 after acquiring an additional 600 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Inspire Medical Systems by 21.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 177,588 shares of the company's stock valued at $32,921,000 after purchasing an additional 31,344 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have weighed in on INSP. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $260.00 target price on shares of Inspire Medical Systems in a report on Tuesday, February 11th. Piper Sandler reduced their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Robert W. Baird lowered their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating for the company in a research note on Tuesday, February 11th. KeyCorp reissued an "overweight" rating and issued a $234.00 target price (down previously from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Finally, Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating on the stock in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $228.82.

Inspire Medical Systems Stock Down 3.3 %

NYSE INSP traded down $5.62 on Tuesday, hitting $165.38. The company's stock had a trading volume of 450,131 shares, compared to its average volume of 580,085. The company's 50-day moving average is $180.18 and its 200 day moving average is $191.19. The firm has a market cap of $4.92 billion, a PE ratio of 95.60, a PEG ratio of 2.86 and a beta of 1.48. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,225 shares of company stock valued at $4,806,530. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.